SFM
IPXL

Soros Fund Management’s Impax Laboratories, Inc. IPXL Stock Holding History

Soros Fund Management’s Portfolio IPXL Stock Details IPXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-61,206
Closed -$2.87M – 308
2015
Q1 		$2.87M Buy
+61,206
New +$2.44M 0.03% 181

Other funds holding IPXL

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
HP
Hound Partners New York $799M AUM 9.54% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
PCM
Pennant Capital Management Summit, New Jersey $212M AUM 19.37% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
AG
Aravt Global New York $11.3M AUM 3.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return

Soros Fund Management's IPXL Position: Q2 2015 in Review

Soros Fund Management sold out of Impax Laboratories, Inc. (IPXL) in Q2 2015, closing a stake of 61,206 shares — an estimated $2.87M sold.

Soros Fund Management first reported a position in IPXL in Q1 2015 and held it in 1 quarter. The position peaked at $2.87M in Q1 2015. 197 funds tracked by Wall St. Rank hold IPXL as of Q2 2015.

  • Soros Fund Management reported no remaining Impax Laboratories, Inc. position as of Q2 2015 after selling out during the quarter.
  • Soros Fund Management sold 61,206 Impax Laboratories, Inc. shares in Q2 2015, an estimated $2.87M.
  • Soros Fund Management first reported a position in Impax Laboratories, Inc. in Q1 2015 and held it in 1 quarter.
  • Soros Fund Management's Impax Laboratories, Inc. position peaked at $2.87M in Q1 2015.
  • 197 funds tracked by Wall St. Rank held Impax Laboratories, Inc. as of Q2 2015.

Based on Soros Fund Management's 13F filing for Q2 2015, filed 14 Aug 2015.